(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
Portfolio Pulse from Benzinga Insights
Alnylam Pharmaceuticals (NYSE:ALNY) has seen a decrease in short interest, now at 4.33 million shares or 4.56% of float, down 8.43% from the last report. It would take about 7.96 days to cover all short positions. This change in short interest could indicate a shift in market sentiment towards ALNY, potentially signaling increased bullishness. The company's short interest is slightly below its peer group average of 4.64%.
February 06, 2024 | 6:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals's short interest has decreased, indicating a potential shift towards bullish sentiment among investors.
A decrease in short interest often suggests that investors are becoming more optimistic about a company's future prospects. For ALNY, this reduction in short interest could lead to a positive short-term impact on its stock price as it indicates a decrease in bearish sentiment among traders. Additionally, being slightly below its peer group average in short interest might make ALNY more attractive to investors comparing within the sector.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90